粪便免疫化学检测结直肠癌敏感性因分期和部位而异
该研究在435例新诊断结直肠癌患者中评估定量FIT(FOB Gold)对不同T分期、TNM分期及肿瘤部位的敏感性。按厂家推荐 cut-off 17 μg/g,T1期敏感性52%、I期68%,约三分之一I期CRC被漏诊;T1和I期远端结肠敏感性分别为32%和52%。
要点
- 厂家推荐 cut-off 17 μg/g 下,FIT对T1期CRC敏感性仅52%,I期68%。
- T1期敏感性较其他T分期低22%–52%,I期较后期CRC低11%–33%。
- T1和I期远端结肠CRC敏感性分别仅32%和52%。
核心结论
- FIT对CRC总体敏感性高,但按厂家推荐 cut-off 可漏诊约三分之一I期CRC。
研究设计与样本
- 在435例新诊断CRC患者中,治疗前采集粪便,评估定量FIT(FOB Gold)在不同 cut-off 下对T分期、TNM分期和肿瘤部位的敏感性。
主要发现
- cut-off 17 μg/g 时,T1–T4敏感性分别为52%、79%、93%、84%(Ptrend < .0001)。
- cut-off 17 μg/g 时,I–IV期敏感性分别为68%、92%、82%、89%(Ptrend 0.01)。
- 在10–40 μg/g各 cut-off 下,T1期敏感性较其他T分期低22%–52%,I期较后期CRC低11%–33%。
- T1和I期远端结肠CRC敏感性分别为32%和52%。
关键数值与推荐
- 厂家推荐 cut-off 为17 μg/g粪便,替代 cut-off 范围为10–40 μg/g粪便。
临床怎么用
- 解读FIT阴性结果时需考虑分期和部位对敏感性的影响,尤其对I期和远端结肠病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fecal immunochemical tests (FITs) are widely used for colorectal cancer (CRC) screening. FITs detect most CRCs. Although detection of CRC at early stages is most relevant for reducing CRC mortality, there is limited evidence for the stage-specific sensitivity of the FIT in CRC detection. We estimated stage- and location-specific sensitivities of a quantitative FIT in a large cohort of patients with CRC. METHODS: Fecal samples were collected before treatment from 435 patients with newly diagnosed CRC. Sensitivities of a quantitative FIT (FOB Gold, Sentinel Diagnostics; Milano, Italy) for tumors of different T stages and overall TNM stages (according to Union for International Cancer Control) were calculated at the cutoff recommended by the manufacturer (17 μg/g feces) and at alternative cutoffs, ranging from 10 to 40 μg/g feces, overall and stratified by tumor location. RESULTS: At the cutoff recommended by the manufacturer, the FIT detected T1 tumors with 52% sensitivity (95% CI, 37%-67%), T2 tumors with 79% sensitivity (95% CI, 68%-88%), T3 tumors with 93% sensitivity (95% CI, 89%-95%), and T4 tumors with 84% sensitivity (95% CI, 72%-92%) (Ptrend < .0001). The FIT detected stage I cancers with 68% sensitivity (95% CI, 57%-78%), stage II cancers with 92% sensitivity (95% CI, 87%-96%), stage III cancers with 82% sensitivity (95% CI, 73%-89%), and stage IV cancers with 89% sensitivity (95% CI, 80%-95%) (Ptrend 0.01). The FIT detected T1 colorectal tumors with sensitivity values that were 22%-52% lower than for tumors of other T stages and stage I CRC with sensitivity values that were 11%-33% lower than for later-stage CRCs, at any of the evaluated cutoff values. The FIT detected T1 and stage I CRCs in the distal colon with sensitivity values of 32% and 52%, respectively. CONCLUSIONS: Although the FIT identifies patients with CRC with overall high sensitivity, it can miss approximately one-third of stage I CRCs. Studies are needed to increase noninvasive detection of early-stage CRC.
引用
- Niedermaier T, Tikk K, Gies A, et al. Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location. Clin Gastroenterol Hepatol. 2020. PMID: 31988043. doi:10.1016/j.cgh.2020.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。